Jeffrey P. Mornhinweg

Array ( [id] => 17306320 [patent_doc_number] => 11207403 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-28 [patent_title] => Human cytomegalovirus immunogenic composition [patent_app_type] => utility [patent_app_number] => 17/071817 [patent_app_country] => US [patent_app_date] => 2020-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 22220 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16688332 [patent_doc_number] => 20210070808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION [patent_app_type] => utility [patent_app_number] => 17/070334 [patent_app_country] => US [patent_app_date] => 2020-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17070334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18685190 [patent_doc_number] => 11780908 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-10 [patent_title] => Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use [patent_app_type] => utility [patent_app_number] => 17/066092 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 26 [patent_no_of_words] => 42161 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17066092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18129024 [patent_doc_number] => 11555223 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-17 [patent_title] => Methods for detecting Norovirus [patent_app_type] => utility [patent_app_number] => 17/063078 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17035 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063078 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16791741 [patent_doc_number] => 20210121558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => COMPOSITIONS AND METHODS FOR STABILIZING FLAVIVIRUSES WITH IMPROVED FORMULATIONS [patent_app_type] => utility [patent_app_number] => 17/062923 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17062923 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19209558 [patent_doc_number] => 11998594 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-04 [patent_title] => Anti-cancer plant virus particles linked to HER2 antigens [patent_app_type] => utility [patent_app_number] => 17/039312 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 23 [patent_no_of_words] => 19630 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17898360 [patent_doc_number] => 20220308022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => CHARACTERIZATION OF GENE THERAPY VIRAL PARTICLES USING SIZE EXCLUSION CHROMATOGRAPHY AND MULTI-ANGLE LIGHT SCATTERING TECHNOLOGIES [patent_app_type] => utility [patent_app_number] => 17/635488 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17635488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16755382 [patent_doc_number] => 10973910 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-04-13 [patent_title] => Neoglycoconjugates as vaccines and therapeutic tools [patent_app_type] => utility [patent_app_number] => 17/025978 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 50 [patent_no_of_words] => 25472 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17025978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977636 [patent_doc_number] => 20210221873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => CONSERVED HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE EPITOPE, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/020255 [patent_app_country] => US [patent_app_date] => 2020-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50610 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17020255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17602917 [patent_doc_number] => 11331386 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-17 [patent_title] => Antiviral vaccines with improved cellular immunogenicity [patent_app_type] => utility [patent_app_number] => 16/948257 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 41 [patent_no_of_words] => 17011 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16948257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17755571 [patent_doc_number] => 11395850 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-26 [patent_title] => RSV vaccines and methods of production and use thereof [patent_app_type] => utility [patent_app_number] => 17/015610 [patent_app_country] => US [patent_app_date] => 2020-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13292 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17015610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18216675 [patent_doc_number] => 11591598 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Oligomers and oligomer conjugates [patent_app_type] => utility [patent_app_number] => 17/013374 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 19 [patent_no_of_words] => 65088 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17013374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18056375 [patent_doc_number] => 20220387461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => CANCER VACCINE [patent_app_type] => utility [patent_app_number] => 17/640395 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640395 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552128 [patent_doc_number] => 20230250135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => INFLUENZA VIRUS VACCINES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/753506 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27569 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850579 [patent_doc_number] => 20220280620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => CROSS-REACTIVE EPITOPE FOR MULTIPLE SCLEROSIS [patent_app_type] => utility [patent_app_number] => 17/638005 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17058994 [patent_doc_number] => 11103576 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-08-31 [patent_title] => Measles virus vaccine expressing SARS-COV-2 protein(s) [patent_app_type] => utility [patent_app_number] => 17/010591 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 10209 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17742594 [patent_doc_number] => 11390651 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-19 [patent_title] => Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes [patent_app_type] => utility [patent_app_number] => 17/008025 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 14 [patent_no_of_words] => 28979 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18590479 [patent_doc_number] => 11739363 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Devices and methods for detecting microorganisms using recombinant reproduction-deficient indicator bacteriophage [patent_app_type] => utility [patent_app_number] => 17/003493 [patent_app_country] => US [patent_app_date] => 2020-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 33 [patent_no_of_words] => 24004 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17003493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506434 [patent_doc_number] => 20200385690 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => CULTIVATION OF HUMAN NOROVIRUSES [patent_app_type] => utility [patent_app_number] => 17/000587 [patent_app_country] => US [patent_app_date] => 2020-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23320 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17000587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17163197 [patent_doc_number] => 11149286 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-10-19 [patent_title] => Adenovirus vectors and methods for using adenovirus vectors [patent_app_type] => utility [patent_app_number] => 16/996740 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 202 [patent_figures_cnt] => 86 [patent_no_of_words] => 18030 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996740 [rel_patent_id] =>[rel_patent_doc_number] =>)